Clinical trials: Stroke/Brain Attack
Ischemic Stroke
Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on DA414
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and Food Effects of DA414 Granules in Chinese healthy subjects with single and multiple doses.
- Trial name
- DA414 (NCT06525168)
- Testing
- DA414 Granules
- Where
- China
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Chendu DIAO Nine Hong Pharmaceutical Factory
Acute Ischemic Stroke
Neuroprotection in Acute Cerebral Ischemia II
The goal of this clinical trial is to evaluate whether low-frequency, low-intensity transcranial magnetic stimulation (ELF-MF), delivered by the I-NIC medical device, is effective and safe in treating patients with acute ischemic…
- Trial name
- NCT07552818
- Testing
- Treatment with the I-NIC medical device for neuroprotection
- Volunteers
- 364 people
- Sponsor
- IGEA
Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events
Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events
To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9…
- Trial name
- OPTIMUS-EPIC (NCT07734753)
- Testing
- Alirocumab, Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents)
- Where
- Netherlands
- Volunteers
- 4,006 people
- Sponsor
- Sanofi
Acute Ischaemic Stroke, Transient Ischaemic Attack
THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Study to investigate if the study drug ticagrelor and ASA is more effective than Placebo (inactive tablet) and ASA in preventing new stroke events
- Trial name
- THALES (NCT03354429)
- Testing
- Ticagrelor
- Where
- 387 sites in Argentina, Australia and 26 more
- Volunteers
- 11,016 people
- Sponsor
- AstraZeneca
Acute Ischemic Stroke, Intracranial Stenosis
Acandis Credo Intracranial Stent for Unsuccessful Recanalization After Thrombectomy (ACUTE)
Study objective is to evaluate the efficacy and safety of acute permanent stenting of symptomatic intracranial stenosis following unsuccessful recanalization by thrombectomy in acute ischemic stroke with large vessel occlusion…
- Trial name
- ACUTE (NCT03955835)
- Testing
- Treatment with Credo® stent together with the NeuroSpeed® PTA balloon catheter.
- Where
- 8 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Acandis GmbH
Stroke
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
The purpose of the trial is to determine if extended-release dipyridamole + aspirin [Aggrenox, Asasa ntin] is superior to clopidogrel [Plavix], and if telmisartan [Micardis, Gliosartan, Kinzal, Kinzalm ono, Predxal, Pritor…
- Trial name
- NCT00153062
- Testing
- Aggrenox, Micardis, Clopidogrel
- Where
- 667 sites in United States, Argentina and 34 more
- Volunteers
- 20,332 people
- Sponsor
- Boehringer Ingelheim
Ischemic Stroke
A Study of Survival and Outcome After Stroke
The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain.
- Trial name
- SOS (NCT01193569)
- Where
- United Kingdom
- Volunteers
- 142 people
- Sponsor
- Penumbra Inc.
Type 2 Diabetes Mellitus
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications
- Trial name
- SAVOR- TIMI 53 (NCT01107886)
- Testing
- Saxagliptin
- Where
- 536 sites in United States, Argentina and 25 more
- Volunteers
- 18,206 people
- Sponsor
- AstraZeneca
Stroke
A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke
Research topic. A clinical trial of Danhong injection in treating acute ischemic stroke . Research purpose. To evaluate the efficacy and safety of Danhong injection in treating acute ischemic stroke by a randomized, double-blind…
- Trial name
- NCT02152280
- Testing
- Danhong Injection, Normal Saline
- Volunteers
- 320 people
- Sponsor
- Beijing Bozhiyin T&S Co., Ltd.
Hemiparesis
Post-stroke Motor Rehabilitation Using Functional Near-infrared Spectroscopy-based Brain-computer-interface
Chronic stroke survivors suffering from weaknesses or movement difficulties in their hand/arm are provided a system to aid in at-home rehabilitation for 6 weeks.
- Trial name
- fNIRS-PROMOTE (NCT05258591)
- Testing
- Axem Home
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Axem Neurotechnology Inc.
Cardiovascular Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese Subjects
Part A of this study is a Phase 1, First-in-human (FiH), randomized, single-blind, placebo controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD3366 following single…
- Trial name
- NCT04588727
- Testing
- AZD3366, Ticagrelor, acetylsalicylic acid (ASA)
- Where
- United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947959
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Standard of care
- Where
- Germany
- Volunteers
- 665,533 people
- Sponsor
- Bayer
Acute Ischemic Stroke, Large Vessel Occlusion
Study on the Efficacy and Safety of T-02 for the Treatment for Acute Ischemic Stroke
To examine the revascularization efficacy and safety of T-02 and its associated performance characteristics in treatment of appropriately selected subjects experiencing an acute ischemic stroke when the treatment is initiated…
- Conditions
- Acute Ischemic Stroke, Large Vessel Occlusion, Vascular Occlusion, Thrombosis
- Trial name
- T-02 (NCT05342038)
- Testing
- T-02
- Sponsor
- Biomedical Solutions Inc.
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Atrial Fibrillation
Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke
The GARDENIA registry will collect real-world clinical data on the anticoagulant strategies in patients with AF at elevated risk of stroke but also elevated risk of bleeding.
- Trial name
- GARDENIA (NCT05421533)
- Where
- 96 sites in United States, Argentina and 10 more
- Volunteers
- 705 people
- Sponsor
- Anthos Therapeutics, Inc.
Ischemic Stroke
Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry
To determine the revascularization rate, clinical efficacy and safety of the CE-marked MindFrame System in ischemic stroke patients
- Trial name
- PRIISM2 (NCT01560247)
- Testing
- Mechanical thrombectomy
- Volunteers
- 1,000 people
- Sponsor
- MindFrame, Inc.
Healthy Volunteers
An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants
The purpose of this study is to investigate the effect of taking multiple doses of BMS-986177 when aspirin is taken once-daily. Eligible participants will receive twice-daily doses of BMS-986177 or placebo, with a once-daily dose…
- Trial name
- NCT03341390
- Testing
- Aspirin, BMS-986177
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Stroke, Acute, Stroke, Ischemic
Effects of Atalante Exoskeleton on Gait Recovery in Non- or Poorly Ambulatory Patients With Hemiparesis in the Acute/Subacute Phase (Month 1 to 4)
The present clinical investigation - EarlyExo, is an interventional, international, multicentric, prospective, single-blinded randomized controlled trial.
- Conditions
- Stroke, Acute, Stroke, Ischemic, Stroke, Subacute, Stroke Hemorrhagic
- Trial name
- EarlyExo (NCT06107010)
- Testing
- Use of the Atalante exoskeleton
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 66 people
- Sponsor
- Wandercraft
Stroke, Acute
Post-Market Registry Of Stroke Patients Treated With Medtronic Neuro Thrombectomy Devices to Collect Real World Data in South East Asia
The purpose of this post-market registry is to collect real-world data associated with the use of Medtronic market-released neurothrombectomy devices in acute ischemic stroke (AIS) patients from countries in South East Asia.
- Trial name
- PROSPR-SEA (NCT03364023)
- Testing
- Neurothrombectomy
- Where
- 10 sites in Singapore, Thailand and 1 more
- Volunteers
- 183 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Atrial Fibrillation
Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation
The purpose of the study is to collect additional information of Xarelto treatment in routine clinical practice. Patients affected by atrial fibrillation and who will get Xarelto as a prophylactic treatment against stroke and…
- Trial name
- XaMINA (NCT03284762)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 2 sites in South Korea, Taiwan
- Volunteers
- 1,216 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.